Latest Headlines

Latest Headlines

Xtandi field force gets a staffing boost for market-share battle with Zytiga

Astellas and Medivation bagged that new Xtandi approval in prostate cancer. What next? Gear up for a head-to-head with Johnson & Johnson's Zytiga. And to do that, Medivation is expanding its sales force by 50%, Medical Marketing & Media reports

Astellas leans on U.K. luminaries for cancer R&D

Japanese drugmaker Astellas Pharma has teamed up with Cancer Research U.K. to join forces on early-stage oncology R&D, working to identify new treatments for pancreatic cancer.

U.K.'s NICE throws Astellas a bone on Xtandi--or does it?

First it was good news, then it was bad news, and now it's good news again for Astellas' prostate cancer treatment Xtandi (enzalutamide) and its recommendation from the U.K.'s National Institute for Health and Care Excellence. At least it appears that way.

A certain protein marks tumors that will resist Astellas' prostate cancer drug Xtandi

As Astellas Pharma and Medivation work to broaden the reach of their prostate cancer drug Xtandi, researchers have identified a biomarker that could help proactively spot patients for whom the treatment will not work.

Astellas enlists a wide-eyed animated bladder for Myrbetriq ad campaign

We're accustomed to animated characters in our drug advertising. But a perky... bladder?

Astellas presents The Bladder, animated pitch-organ for overactive-bladder med Myrbetriq

We're accustomed to animated characters in our drug advertising. That cheerful, buzzing Nasonex bee. The gently fluttering Lunesta moth. The droopy, sad little blob that so needs Zoloft. But a perky... bladder?

Medivation, Astellas ask FDA to approve Xtandi for pre-chemo prostate cancer use

Astellas and Medivation today said they are asking the FDA for approval for Xtandi to be used on patients with metastatic castration-resistant prostate cancer who have not received chemotherapy.

Astellas finally bails on Aveo, giving up on the thrice-failed tivozanib

Japan's Astellas Pharma has seen enough of tivozanib, washing its hands of the once-promising cancer drug and putting an end to a three-year collaboration with Aveo Oncology.

Aveo's cancer drug circles the drain after a scuttled Phase II trial

Aveo Oncology and Astellas Pharma are shutting down a Phase II study of tivozanib in breast cancer after failing to enroll enough patients, the partners announced.

On second thought, NICE backs limits on Xtandi use

The U.K.'s National Institute for Health and Care Excellence is known to change its mind. But this time, Britain's cost watchdog has set limitations on its recommendation for prostate cancer pill Xtandi--and maker Astellas is none too happy.